Dosage forms and therapeutic uses of L-4-chlorokynurenine

• US 10,617,663 B2
• Filed: 06/08/2018
• Issued: 04/14/2020
• Est. Priority Date: 01/22/2013
• Status: Active Grant

• Current Assignee: VistaGen Therapeutics, Inc.
• Original Assignee: VistaGen Therapeutics, Inc.
• Inventors: Snodgrass, H. Ralph, Cato, Allen E., Hicklin, Jack S.
• Primary Examiner(s): Cruz, Kathrien A
• Application Number:
  US16/003,793
• Publication Number:
  US 20180289649A1
• Time in Patent Office: 676 Days
• Field of Search: 514564
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.

Claims

1. A method of treating depression comprising the step of administering to a human patient in need thereof a therapeutically effective amount of L-4-chlorokynurenine, wherein the L-4-chlorokynurenine is administered in an amount ranging from 360 mg to 1440 mg.

2. The method of claim 1, wherein the L-4-chlorokynurenine is administered in a pharmaceutical composition comprising L-4-chlorokynurenine and a pharmaceutically acceptable carrier or excipient.

3. The method of claim 2, wherein the patient is administered L-4-chlorokynurenine daily from 1 to about 30 days.

4. The method of claim 2, wherein the pharmaceutical composition is orally administered to the patient.

5. The method of claim 2, wherein the pharmaceutical composition is selected from the group consisting of a tablet, a capsule, a liquid suspension, a solid solution, a softgel composition, an injectable composition, a topical composition, a transdermal composition, a suppository and a nasal delivery composition.

6. The method of claim 2, wherein the depression treated is major depression.

7. The method of claim 1, wherein the depression treated is major depression.

8. The method of claim 6, wherein the pharmaceutical composition is a tablet or a capsule.

9. The method of claim 2, wherein the pharmaceutical composition is a tablet or a capsule.